Recently, silencing of KIF14 downregulated p-AKT by its direct interaction at the plasma membrane [33, 34, 36–38] and reversed drug resistance to docetaxel but not to doxorubicin, carboplatin, or gemcitabine in breast cancer, indicating the function of KIF14 in altering drug resistance by effectively targeting antitumor drugs [38]. The gene discussed is AKT1; the disease is breast carcinoma.